The stock price of ProKidney Corp (NASDAQ: PROK) has surged by 21.49 when compared to previous closing price of 0.75, but the company has seen a 28.17% gain in its stock price over the last five trading sessions. zacks.com reported 2025-03-21 that PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is It Worth Investing in ProKidney Corp (NASDAQ: PROK) Right Now?
The 36-month beta value for PROK is also noteworthy at 1.60. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for PROK is 92.44M, and at present, short sellers hold a 12.90% of that float. The average trading volume of PROK on April 24, 2025 was 694.61K shares.
PROK’s Market Performance
PROK stock saw a decrease of 28.17% in the past week, with a monthly decline of -10.77% and a quarterly a decrease of -45.50%. The volatility ratio for the week is 21.70%, and the volatility levels for the last 30 days are 22.22% for ProKidney Corp (PROK). The simple moving average for the last 20 days is 20.47% for PROK stock, with a simple moving average of -47.39% for the last 200 days.
Analysts’ Opinion of PROK
Guggenheim, on the other hand, stated in their research note that they expect to see PROK reach a price target of $6. The rating they have provided for PROK stocks is “Buy” according to the report published on September 10th, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to PROK, setting the target price at $3 in the report published on March 07th of the previous year.
PROK Trading at -11.49% from the 50-Day Moving Average
After a stumble in the market that brought PROK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.50% of loss for the given period.
Volatility was left at 22.22%, however, over the last 30 days, the volatility rate increased by 21.70%, as shares sank -9.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.76% lower at present.
During the last 5 trading sessions, PROK rose by +28.17%, which changed the moving average for the period of 200-days by -59.55% in comparison to the 20-day moving average, which settled at $0.7555. In addition, ProKidney Corp saw -46.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PROK starting from Control Empresarial de Capital, who purchase 25,000 shares at the price of $0.75 back on Apr 17 ’25. After this action, Control Empresarial de Capital now owns 73,455,330 shares of ProKidney Corp, valued at $18,690 using the latest closing price.
Control Empresarial de Capital, the Add’l Rep. Persons-see Ex.99-1 of ProKidney Corp, purchase 100,000 shares at $0.75 during a trade that took place back on Apr 16 ’25, which means that Control Empresarial de Capital is holding 73,430,330 shares at $74,820 based on the most recent closing price.
Stock Fundamentals for PROK
Current profitability levels for the company are sitting at:
- -2416.79 for the present operating margin
The net margin for ProKidney Corp stands at -1344.07. The total capital return value is set at -0.45.
Based on ProKidney Corp (PROK), the company’s capital structure generated -0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -51.13. The debt to equity ratio resting at -0.0. The interest coverage ratio of the stock is -20408.44.
Currently, EBITDA for the company is -158.49 million with net debt to EBITDA at 0.61. When we switch over and look at the enterprise to sales, we see a ratio of 2233.36. The receivables turnover for the company is 0.03for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.93.
Conclusion
In summary, ProKidney Corp (PROK) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
